In recent developments, renowned TV personality
Jim Cramer stated considerable respect for
Danaher Corporation while pointing out the company's sub-par performance and guidance. On a brighter note, analysis explains that
Danaher remains a resourceful investment position with intrinsic value despite a perceivable drop in China Core Revenue in Q3.
Scotiabank has newly started covering Danaher with a Sector Perform recommendation. The quarterly dividend payment for January 2025 is pitched at
$0.27. Some entities such as
Parnassus Growth Equity Fund have sold their stake in
Danaher, while others like
Baron Health Care Fund have added the company to their portfolio. The Q3 earnings report highlights a resilient performance amidst market challenges. Furthermore, diagnostic sales experienced a year-on-year increase, outperforming estimates. Meanwhile, recognized asset management firms have reduced their shares in the company. Finally, the company has received
buy ratings from financial institutions such as
Guggenheim and
Bank of America.
Danaher Corporation DHR News Analytics from Tue, 23 Apr 2024 07:00:00 GMT to Sat, 28 Dec 2024 21:16:52 GMT -
Rating 5
- Innovation -4
- Information 1
- Rumor -1
